Browse recruiting and upcoming clinical trials for Waldenström macroglobulinemia.
Patient-friendly, AI-assisted summaries based on official ClinicalTrials.gov ↗ records. Last updated: Oct 10, 2026
About this listHide
ClinicalTrials.gov is the complete and most up-to-date source. Trials may be missing, and trial information may have changed since our last check. Always verify important information in the official registry.
Who can join AIAdults (≥18 years) with mature B‑cell malignancies: CLL/SLL, mantle cell lymphoma, DLBCL, follicular lymphoma, or Waldenström macroglobulinemia.
What is being studied AITests safety, drug levels, and preliminary activity of rocbrutinib combined with lacutoclax in B‑cell cancers.
Who can join AIAdults (18+) with relapsed or refractory CLL/SLL, DLBCL (including Richter transformation), MCL, Waldenström macroglobulinemia, MZL, or follicular lymphoma.
What is being studied AITests safety, dosing, pharmacology, and early activity of oral APG-3288 in relapsed/refractory blood cancers.
Who can join AIPeople with relapsed, progressive, or refractory B‑cell lymphomas (for example DLBCL, FL, PMBCL, HGBCL, or Waldenström macroglobulinemia).
What is being studied AITests intravenous MDX2003 for safety, dosing, pharmacokinetics, immunogenicity, and early anti-lymphoma activity.
Who can join AIPeople with previously treated B‑cell malignancies, including diffuse large B‑cell lymphoma, follicular lymphoma, mantle cell lymphoma, marginal‑zone B‑cell lymphoma, Waldenström macroglobulinemia, and other B‑cell non‑Hodgkin lymphomas.
What is being studied AITests safety, best dose, and preliminary efficacy of LY4152199 in treated B-cell malignancies
Who can join AIAdults with Waldenström macroglobulinemia (lymphoplasmacytic/indolent B‑cell lymphoma) with symptomatic disease and ≥2 prior treatments.
What is being studied AITests the safety and efficacy of pacritinib in participants with Waldenström macroglobulinemia.
Who can join AIPeople with relapsed or refractory CLL or SLL, and select low‑grade B‑cell lymphomas (e.g., marginal zone lymphoma, lymphoplasmacytic lymphoma/Waldenström).
What is being studied AITests safety, dosing, and early anti-tumor activity of lonitoclax in relapsed or refractory B-cell malignancies.
Who can join AIPeople with relapsed or refractory B‑cell non-Hodgkin lymphoma, including DLBCL, follicular, mantle cell, marginal zone, and Waldenstrom macroglobulinemia.
What is being studied AITests a single IV infusion of SynKIR-310 (autologous T cells transduced with CD19 KIR‑CAR).
Who can join AIAdults (≥18) with relapsed or refractory B‑cell lymphomas such as follicular, mantle cell, large B‑cell, hairy cell, Waldenström (lymphoplasmacytic), Burkitt, or marginal zone lymphoma.
What is being studied AITests safety, dose, and response to CD22 CAR T-cell therapy in adults with relapsed or refractory B‑cell lymphomas.
Who can join AIAdults with relapsed or refractory B-cell malignancies (for example: CLL, SLL, MCL, FL, non-GCB DLBCL, MZL, or Waldenström macroglobulinemia).
What is being studied AITests safety, tolerability, pharmacokinetics, and preliminary anti-malignancy activity of AC676.
Who can join AIPeople with B-cell malignancies, including CLL/SLL, Waldenstrom macroglobulinemia, mantle cell, marginal zone, follicular lymphoma, or other NHL.
What is being studied AITests oral docirbrutinib (AS-1763) for safety, dosing, and preliminary activity in treated B‑cell cancers.
Who can join AIAdults (18+) with certain B‑cell malignancies such as MCL, CLL/SLL, MZL, FL (grade 1–3a), WM, non‑GCB DLBCL, or Richter's transformation.
What is being studied AITests safety, dosing, and preliminary anti-tumor activity of oral BGB-16673 monotherapy.
Who can join AIAdults (≥18) with relapsed or refractory CD19‑positive B‑cell non‑Hodgkin lymphomas (dose-expansion cohorts currently open are Burkitt lymphoma and marginal zone lymphoma/Waldenström).
What is being studied AITests safety, dosing, and feasibility of anti-CD19 CAR-T cell therapy.
Who can join AIPeople ≤60 years with various blood cancers or acquired bone marrow failure (eg, AML, ALL, MDS, CLL, NHL, multiple myeloma) considered for myeloablative allogeneic HSCT.
What is being studied AITests two myeloablative transplant preparative regimens followed by post-transplant cyclophosphamide GVHD prophylaxis.
Who can join AIAdults (18+) with indolent lymphomas, including CLL/SLL, follicular, marginal zone, lymphoplasmacytic/Waldenström, or cutaneous T‑cell lymphoma.
What is being studied AITests a personalized exercise and diet program for cancer-related fatigue.
Who can join AIPeople with chronic lymphocytic leukemia or related B‑cell disorders who are beginning Bruton tyrosine kinase (BTK) inhibitor treatment.
What is being studied AITests continuous implanted heart monitoring to detect arrhythmias in people starting Bruton tyrosine kinase inhibitors.
Who can join AIPeople with B‑cell malignancies (for example CLL, mantle cell lymphoma, marginal zone lymphoma, or Waldenström macroglobulinemia) who are starting or receiving BTKi treatment.
What is being studied AIMeasures blood pressure changes and heart hemodynamics in people on Bruton tyrosine kinase inhibitors.
Who can join AIAdults (≥18) with Waldenström's macroglobulinemia, chronic lymphocytic leukemia, marginal zone lymphoma, or follicular lymphoma planned for zanubrutinib (for FL: zanubrutinib + obinutuzumab) per the product label.
What is being studied AICollects real-world data on zanubrutinib use, effectiveness, safety, quality of life, and resource use.
Who can join AIPeople with precursor or early-stage blood disorders (MGUS, smoldering multiple myeloma, Waldenstrom macroglobulinemia, early MDS, monoclonal B‑cell lymphocytosis, or other low‑grade B‑cell malignancies).
What is being studied AICollects blood, bone marrow and tissue to find molecular (DNA) changes in early blood disorders.
Who can join AIPeople being evaluated for a hematologic cancer or related blood or lymphoid disorder (leukemia, lymphoma, multiple myeloma, myelodysplastic and myeloproliferative disorders, and related neoplasms) at the University of North Carolina Hospitals — in the hematology/oncology clinics, the stem cell transplant clinic, or as an inpatient.
What is being studied AICollects and stores blood, tissue, and body-fluid samples for future laboratory research.
Who can join AIAdults with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) or lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia (LPL/WM). People with MBL or splenic marginal zone lymphoma are no longer enrolled.
What is being studied AICollects blood, tissue, and imaging to study disease biology and progression.
Who can join AIAdults with chronic lymphocytic leukemia, Waldenström macroglobulinemia, mantle cell lymphoma, or marginal zone lymphoma who are newly starting BTKI or non-BTKI therapy.
What is being studied AISmartwatch and 14-day ECG patch monitoring for atrial fibrillation and other arrhythmias over 12 months.
Who can join AIPeople with clonal blood disorders or monoclonal gammopathies, including MGUS, multiple myeloma, Waldenström macroglobulinemia, myelodysplastic syndrome, or Schnitzler syndrome.
What is being studied AICollects genomic, transcriptomic and inflammatory (cytokine/functional) data from tumor and blood cells.
Who can join AIPeople with Diffuse Large B-cell Lymphoma, Multiple Myeloma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Chronic Lymphocytic Leukemia, or Waldenström Macroglobulinemia.
What is being studied AITests a new PET tracer (18F-BL40) against standard 18F-FDG to image CXCR4-expressing tumors.
Trials that may include Waldenström macroglobulinemia (1)
ClinicalTrials.gov returned these when we searched for this condition, but we could not confirm from the registry records that they are intended for people with it. Check each trial’s eligibility criteria, and ask the study team if you are unsure.
Who can join AIPeople with advanced cutaneous squamous cell carcinoma, including kidney transplant recipients and people with certain hematologic (blood) cancers.
What is being studied AITests cosibelimab's safety and tumor response in people with advanced cutaneous squamous cell carcinoma.